Article Text

Download PDFPDF
Paediatric palliative care: intravenous methylnaltrexone relieves constipation
  1. Daniel Yeomanson1,
  2. Osman Chohan2 and
  3. Anton Mayer3
  1. 1Department of Paediatric Oncology, Sheffield Children's Hospital, Sheffield, UK
  2. 2Pharmacy Department, Sheffield Children's Hospital, Sheffield, UK
  3. 3Bluebell Wood Children's Hospice, Sheffield, UK
  1. Correspondence to Dr Daniel Yeomanson, Department of Paediatric Oncology, Sheffield Children's Hospital, Western Bank, Sheffield S10 2TH, UK; Daniel.Yeomanson{at}sch.nhs.uk

Abstract

Methylnaltrexone, a peripheral opioid μ-receptor antagonist is licensed for subcutaneous administration for the treatment of severe opioid-induced constipation in adults. We describe the use of intravenous methylnaltrexone in a 3-year-old boy receiving a subcutaneous diamorphine infusion for palliation from widely metastatic alveolar rhabdomyosarcoma. The patient, who had not opened his bowels for 3 weeks despite use of regular conventional laxatives, was given a 150 mcg/kg dose via indwelling central venous catheter. Constipation was relieved within minutes of the injection. There were no side effects noted during or following injection, and no clinically apparent reduction in analgesia. Intravenous methylnaltrexone may provide a valuable additional treatment option in paediatric palliative care, especially for those with an oncological diagnosis, the majority of whom will have indwelling central venous access devices.

  • Cancer
  • Paediatrics
  • Drug administration

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.